Kestra Private Wealth Services LLC cut its stake in  Laboratory Co. of America Holdings (NYSE:LH – Get Rating) by 46.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,125 shares of the medical research company’s stock after selling 1,813 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Laboratory Co. of America were worth $500,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Yousif Capital Management LLC increased its stake in  Laboratory Co. of America by 0.3% during the fourth quarter. Yousif Capital Management LLC now owns 13,133 shares of the medical research company’s stock worth $3,093,000 after acquiring an additional 42 shares during the last quarter.  Hanson & Doremus Investment Management increased its position in shares of  Laboratory Co. of America by 4.1% during the 4th quarter. Hanson & Doremus Investment Management now owns 1,125 shares of the medical research company’s stock worth $265,000 after purchasing an additional 44 shares during the last quarter.  SP Asset Management raised its holdings in  Laboratory Co. of America by 0.3% in the 3rd quarter. SP Asset Management now owns 15,369 shares of the medical research company’s stock valued at $3,148,000 after buying an additional 45 shares during the period.  Allen Investment Management LLC lifted its position in  Laboratory Co. of America by 3.5% in the third quarter. Allen Investment Management LLC now owns 1,346 shares of the medical research company’s stock valued at $276,000 after buying an additional 46 shares during the last quarter.  Finally, Harbor Investment Advisory LLC boosted its stake in  Laboratory Co. of America by 2.2% during the third quarter. Harbor Investment Advisory LLC now owns 2,200 shares of the medical research company’s stock worth $451,000 after buying an additional 47 shares during the period. Hedge funds and other institutional investors own  89.70% of the company’s stock.

A number of equities research analysts have recently issued reports on LH shares. Credit Suisse Group reduced their price target on shares of Laboratory Co. of America from $304.00 to $288.00 and set an “outperform” rating on the stock in a research note on Monday, March 13th. Wells Fargo & Company decreased their price target on Laboratory Co. of America from $315.00 to $290.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 21st. Truist Financial lifted their price objective on Laboratory Co. of America from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Friday, February 17th. Citigroup increased their target price on Laboratory Co. of America from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Friday, February 17th. Finally, StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Wednesday, April 12th. Two equities research analysts have rated the stock with a hold rating and eight have issued  a buy rating to the stock. According to data from MarketBeat, the company  has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.

In related news, EVP Der Vaart Sandra D. Van sold 219 shares of the company’s stock in a transaction that occurred on Tuesday, February 7th. The stock was sold at an average price of $243.01, for a total value of $53,219.19. Following the completion of the transaction, the executive vice president now directly owns 5,341 shares of the company’s stock, valued at $1,297,916.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Der Vaart Sandra D. Van sold 219 shares of Laboratory Co. of America stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $243.01, for a total transaction of $53,219.19. Following the sale, the executive vice president now directly owns 5,341 shares in the company, valued at approximately $1,297,916.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark S. Schroeder sold 3,897 shares of the company’s stock in a transaction on Friday, March 31st. The shares were sold at an average price of $225.81, for a total transaction of $879,981.57. Following the completion of the transaction, the executive vice president now owns 6,687 shares of the company’s stock, valued at approximately $1,509,991.47. The disclosure for this sale can be found here. Insiders sold 12,598 shares of company stock valued at $3,058,283 in the last ninety days. Insiders own  0.65% of the company’s stock.

Shares of Laboratory Co. of America stock opened at $230.25 on Wednesday. The business has a 50-day simple moving average of $232.78 and a 200-day simple moving average of $233.62. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.35 and a current ratio of 1.50. Laboratory Co. of America Holdings has a one year low of $200.32 and a one year high of $280.72. The company has a market cap of $20.38 billion, a PE ratio of 16.61 and a beta of 1.04.

Laboratory Co. of America (NYSE:LH – Get Rating) last posted its quarterly earnings results on Thursday, February 16th. The medical research company reported $4.14 EPS for the quarter, topping the consensus estimate of $4.06 by $0.08. The company had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Laboratory Co. of America had a net margin of 8.60% and a return on equity of 17.68%. The firm’s revenue was down 9.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.77 EPS.  On average, equities research analysts forecast that  Laboratory Co. of America Holdings will post 17.18 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Wednesday, May 17th. Laboratory Co. of America’s dividend payout ratio  is presently 20.78%.

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions.

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.